Patents Examined by Rebecca Cook
  • Use of nitroxides for the treatment of essential hypertension
    Patent number: 6617337
    Abstract: The present invention encompasses methods of treating patients for essential hypertension. The invention also includes related pharmaceutical compositions of nitroxides. Specific drugs, such as 4-hydroxy-2,2,6,6-tetramethyl-1-piperidinyloxy (Tempol) are disclosed. These compositions are also contemplated for use in the treatment of oxidative stress and modulation of blood pressure.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: September 9, 2003
    Assignee: Georgetown University
    Inventor: Christopher S. Wilcox
  • Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
    Patent number: 6613802
    Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: September 2, 2003
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • Use of tetracycline derivatives in treating multiple sclerosis
    Patent number: 6613756
    Abstract: A method of treating multiple sclerosis is disclosed. In one embodiment, the method comprises the step of treating a multiple sclerosis patient with a tetracycline derivative, wherein the multiple sclerosis symptoms of the patient are diminished.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: September 2, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ian D. Duncan, Su-Chun Zhang
  • Use of R(+) -&agr;-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piper idinemethanol for the treatment of sleep disorders
    Patent number: 6613779
    Abstract: A method of treating a patient for a Sleep Disorder comprising administering an effective amount of R-(+)-&agr;-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: September 2, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Cesare Mondadori, Stephen Sorensen, Janice M. Hitchcock
  • Treatment of female arousal disorder
    Patent number: 6613768
    Abstract: A method of treating female arousal disorder (FAD) in a female patient is disclosed. The method includes orally administering an agent that inhibits cyclic guanosine 3′5′-monophosphate specific phosphodiesterase type 5 to the female patient.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: September 2, 2003
    Assignee: Lilly ICOS LLC
    Inventors: Lora L. Allemeier, Diane L. Brashear, Kenneth M. Ferguson, William E. Pullman
  • Anti-constipation composition
    Patent number: 6610732
    Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: August 26, 2003
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
    Patent number: 6610719
    Abstract: This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Vishwas M. Paralkar, David D. Thompson
  • 6-methoxy-2-naphthylacetic acid prodrugs
    Patent number: 6610739
    Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition is Additional alternative embodiments are R or R″ that are therapeutic moieties.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: August 26, 2003
    Assignee: Nobex Corporation
    Inventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs
  • Methods of treating fibromyalgia
    Patent number: 6602911
    Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 5, 2003
    Assignee: Cypress Bioscience, Inc.
    Inventors: Jay D. Kranzler, Srinivas G. Rao
  • Method of local anesthesia and analgesia
    Patent number: 6599906
    Abstract: The present invention provides a method of producing local analgesia and anesthesia in a mammal experiencing pain in a nerve tissue region. The method includes topically administrating to the region, in a suitable pharmaceutical vehicle, an effective dose of a sodium channel blocking compound.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: July 29, 2003
    Assignee: Wex Medical Instrumentation Co., Ltd.
    Inventors: Baoshan Ku, Shiquan Qi
  • Cosmetic and dermatological preparation with flavonoids
    Patent number: 6596761
    Abstract: The invention relates to cosmetic and dermatological formulations having a) a content of a compound or several compounds from the group consisting of flavonoids, or having b) a content of an active compound combination comprising a compound or several compounds chosen from the group consisting of flavonoids in combination with a compound or several compounds chosen from the group consisting of cinnamic acid derivatives and c) if appropriate an additional content of a compound or several compounds from the group consisting of antioxidants.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: July 22, 2003
    Assignee: Beiersdorf AG
    Inventors: Ghita Lanzendörfer, Franz Stäb, Sven Untiedt
  • Treatment of fibromyalgia
    Patent number: 6596756
    Abstract: A method of using N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine to treat persistent pain.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: July 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: David Joel Goldstein, Smriti Iyengar, Rosa Marie Ademe Simmons
  • Method for the treatment or prevention of coronary graft vasospasm
    Patent number: 6593329
    Abstract: Levosimendan, or (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment or prevention of coronary graft vasospasm after coronary artery by-pass surgery.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: July 15, 2003
    Assignee: Orion Corporation
    Inventors: Lasse Lehtonen, Julius Papp, Janos Szecsi
  • Method for treatment of pain
    Patent number: 6593331
    Abstract: A method of treating pain with acetaminophen comprises the concurrent administration of a hydroxyazapirone selected from 6-hydroxybuspirone or 3-hydroxygepirone. This combination of agents results in a more morphine-like analgesic response characterized by rapid onset and greater pain relief.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: July 15, 2003
    Assignees: Laboratories UPSA, Bristol-Myers Squibb Company
    Inventors: Francoise Camborde, Alix Cloarec, Charles Conway
  • Treating vancomycin-intermediates and multiresistant staphylococci infection with thiamphenicol or a salt thereof
    Patent number: 6589993
    Abstract: The present invention relates to methods of treating vancomycin-intermediates and multiresistant staphylococci infection using thiamphenicol or a salt thereof.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: July 8, 2003
    Assignee: Zambon Group S.p.A.
    Inventors: Domenico Ungheri, Luciano Licciardello
  • Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
    Patent number: 6586417
    Abstract: This invention relates to a method of administering an effective amount of at least one of the ester or ether derivatives of 4-hydroxy 4-androstenedione for the regulation of athletic function in humans.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: July 1, 2003
    Assignee: NutriSport Pharmacal, Inc.
    Inventor: Sal Abraham
  • Antidiabetic formulation and method
    Patent number: 6586438
    Abstract: A low dose antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes in drug naive patients, which includes a combination of metformin (employed in a reduced amount (less than 800 mg metformin per day) compared to that employed in generally accepted medical practice) and at least one other antidiabetic agent such as a sulfonyl urea, for example, glyburide, which combination provides at least about substantially equivalent efficacy in treating diabetes in drug naive patients, as do antidiabetic formulations containing metformin employed in dosages prescribed in generally accepted medical practice for first line therapy in treating diabetes, but with substantially reduced side effects, such as hypoglycemia and/or gastrointestinal distress.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: July 1, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventor: Beth Anne Piper
  • Use of a celecoxib composition for fast pain relief
    Patent number: 6579895
    Abstract: There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises orally administering to the subject an effective pain-relieving amount of a composition comprising celecoxib formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of celecoxib in which a concentration of about 250 ng/ml is attained not later than about 30 minutes after oral administration.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: June 17, 2003
    Assignee: Pharmacia Corporation
    Inventors: Aziz Karim, Andrew M. Brugger, Ping Gao, Fred Hassan, James C. Forbes
  • Methods for treating cognitive impairments caused by traumatic brain injuries
    Patent number: 6576646
    Abstract: The invention describes novel methods for treating and preventing cognitive impairments caused by traumatic brain injuries by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinestrease inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT®.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: June 10, 2003
    Assignee: Eisai Co., Ltd.
    Inventor: Raymond Pratt
  • Therapeutic uses of melatonin
    Patent number: 6566389
    Abstract: A method for treating or preventing symptoms of tardive dyskensia comprises administering melatonin to patient exhibiting or liable to develop such symptoms. The melatonin is administered in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: May 20, 2003
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Nava Zisapel, Moshe Laudon